Current Report Filing (8-k)
September 30 2020 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
September
30, 2020
Date
of Report
(Date
of earliest event reported)
OZOP
SURGICAL CORP.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-55976
|
|
35-2540672
|
(State
or other jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
31
Sandfort Ln., Warwick NY 10990
(Address
of principal executive offices, including zip code)
(845)
544-5112
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
N/A
|
|
N/A
|
Item
7.01 Regulation FD Disclosure.
On
September 30, 2020, the Company issued a press release regarding the execution of a Technology Development Agreement and a Sales
Representative Agreement between its wholly owned subsidiary, Power Conversion Technologies, Inc., and Precision Power Products
(India) Private Limited. A copy of the press release issued by the Company is attached as Exhibit 99.1 to this Current Report
on Form 8-K, which is incorporated by reference solely for purposes of this Item 7.01 disclosure.
Exhibit
99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to
future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these
forward-looking statements
The
information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference
in such a filing.
Item
8.01 Other Events.
On
September 30, 2020, the Company, through its wholly owned subsidiary, Power Conversion Technologies, Inc. (“PCTI”)
entered into a Technology Development Agreement (the “Development Agreement”) and a Sales Representative Agreement
(the “Sales Rep Agreement”) with Precision Power Products (India) Private Limited (“PPP”).
Under
the terms of the Development Agreement, PPP shall provide certain specifications and design concepts to PCTI and PCTI shall design,
engineer and develop one or more prototype(s) to be licensed to PPP for the manufacture and sale of certain products, which shall
be based in whole or in part by the prototype(s). As consideration, if PCTI provides a full design of the product(s), PPP shall
pay 100% of the invoice value for the product(s) produced, if PCTI provides a partial design of the product(s), PPP shall pay
50% of the invoice value for the product(s) produced. If jointly designed by PCTI and PPP, PPP shall pay 0% of the invoice value.
Additionally, PCTI shall receive an ongoing 10% royalty fee of products it produces for and are sold by PPP.
Under
the terms of the Sales Rep Agreement, PCTI granted to PPP an exclusive right to solicit orders for products it produces for and
are sold by PPP in the Indian Subcontinent, the Middle East and North Africa, Southeast Asia, Eastern Europe and the Commonwealth
of Independent States.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
September 30, 2020
|
OZOP
SURGICAL CORP.
|
|
|
|
|
By:
|
/s/
Brian Conway
|
|
Name:
|
Brian
Conway
|
|
Title:
|
Chief
Executive Officer
|
Ozop Energy Solutions (PK) (USOTC:OZSC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ozop Energy Solutions (PK) (USOTC:OZSC)
Historical Stock Chart
From Sep 2023 to Sep 2024